Table 2 Comparison of HIV-infected patients vs patients with other immunosuppressive underlying conditions vs patients without any identified underlying immunodeficiency
All patients n = 40 | HIV- infected n = 23 | Other immunodeficiency n = 11 | No identified immunodeficiency n = 6 | p-value | |
|---|---|---|---|---|---|
Female, n (%) | 14 (36) | 7 (32) | 6 (55) | 1 (17) | 0.272 |
Age, years | 56 (43–61) | 49 (41–57) | 62 (60–70) | 57 (46–70) | 0.002 |
SOFA | 11 (8–15) | 12 (8–16) | 12 (9–16) | 7 (6–10) | 0.260 |
Geographic origin, French Guyana, n (%) | 13 (33) | 10 (44) | 1 (9) | 2 (33) | 0.134 |
HAART, n (%) | 7 (18) | 7 (30) | 0 (0) | 0 (0) | – |
Time between | |||||
Symptoms onset and ICU admission, days | 22 (14–30) | 22 (15–29) | 15 (10–23) | 40 (31–78.) | 0.027 |
Symptoms onset and treatment, days | 23 (15–40) | 22 (16–31) | 16 (11–27) | 44 (41–79) | 0.001 |
ICU admission and treatment, days | 1 (0–2) | 1 (0–1) | 2 (1–5) | 3 (0–8) | 0.264 |
Clinical features | |||||
Temperature, °C | 39 (38– 40) | 39 (38–40) | 39 (37–39) | 38 (38–39) | 0.422 |
Neurological symptoms, n (%) | 16 (40) | 8 (35) | 6 (55) | 2 (33) | 0.602 |
Gastro intestinal symptoms, n (%) | 23 (58) | 17 (74) | 5 (46) | 1 (17) | 0.026 |
Respiratory symptoms, n (%) | 38 (95) | 22 (96) | 11 (100) | 5 (83) | 0.351 |
Biological data | |||||
Lactate, mmol/L | 3 (2–5) | 3 (2–5) | 3 (2–4) | 2 (2–3) | 0.247 |
Ferritinemia, UI/L | 35000 (3000–40000) | 40000 (22500–43750) | 16631 (3012–40000) | 1130 (1000–2500) | 0.012 |
Platelets, G/L | 67 (16–149) | 26 (13–102) | 76 (27–111) | 176 (126–238) | 0.028 |
Creatinine, µmol/L | 140 (84–374) | 111 (84–348) | 239 (114–448) | 122 (84–191) | 0.492 |
Triglycerides, mmol/L | 3 (2–3) | 3 (3–4) | 3 (3–3) | 2 (2–2) | 0.297 |
LDH, UI/L | 662 (400–1054) | 1000 (600–1500) | 500 (409–840) | 252 (223–272) | 0.001 |
CRP, mg/L | 150 (93–246) | 158 (94–234) | 200 (112–314) | 95 (83–126) | 0.205 |
CD4 count, mm−3 | 20 (10–27) | 20 (10–27) | NA | NA | – |
Severe organ involvement | |||||
Acute respiratory failure, n (%) | 34 (85) | 20 (87) | 11 (100) | 3 (50) | 0.024 |
Shock, n (%) | 31 (78) | 18 (78) | 9 (82) | 4 (67) | 0.756 |
Coma, n (%) | 12 (30) | 7 (30) | 4 (36) | 1 (17) | 0.802 |
Hemophagocytosis lymphohistiocytosis, n (%) | 19 (48) | 15 (65) | 3 (27) | 1 (17) | 0.044 |
Disseminated histoplasmosis, n (%) | 32 (80) | 22 (96) | 9 (82) | 1 (17) | < 0.001 |
Advanced life support therapy | |||||
Renal replacement therapy, n (%) | 22 (55) | 14 (61) | 6 (55) | 2 (33) | 0.550 |
Mechanical ventilation, n (%) | 31 (78) | 19 (83) | 8 (73) | 4 (67) | 0.655 |
Outcome | |||||
30-day mortality, n (%) | 21 (53) | 14 (61) | 3 (27) | 4 (67) | 0.151 |
Length of ICU stay (days) | 6 (4–11) | 6 (4–9) | 6 (4–12) | 8 (3–22) | 0.796 |